Clinical Trials Logo

Filter by:
NCT ID: NCT04834115 Recruiting - Covid19 Clinical Trials

Efficacy of Ivermectin in Outpatients With Non-severe COVID-19

Start date: November 17, 2020
Phase: Phase 3
Study type: Interventional

This is a randomized controlled trial to evaluate the efficacy of ivermectin in reducing the risk of progression to severe disease and hospitalizations in COVID-19 patients.

NCT ID: NCT04809701 Enrolling by invitation - Clinical trials for Ventricular Arrythmia

Non-vascular ICD Electrode Configuration Feasibility Study

Start date: March 22, 2021
Phase: N/A
Study type: Interventional

This study is designed to evaluate the energy requirements of two different Nonvascular ICD (NV-ICD) electrode configurations for achieving successful defibrillation of ventricular arrhythmias.

NCT ID: NCT04783779 Recruiting - Clinical trials for End Stage Renal Disease

Evaluation of STARgraft-2 for Hemodialysis Access

Start date: February 16, 2021
Phase: N/A
Study type: Interventional

This study is a single site, prospective, single arm evaluation of the safety and effectiveness of the Healionics STARgraft-2 hemodialysis access graft. STARgraft devices have been demonstrated in preclinical and other studies to have improved resistance to the common failure modes of venous anastomosis stenosis and infection. This study is an extension from a prior First in Human (FIH) study (NCT03916731) with the STARgraft AV investigational device. That study also included control implants of commercially available standard ePTFE grafts approved for the same use. The study is enrolling patients with End Stage Renal Disease (ESRD) requiring hemodialysis via a prosthetic vascular graft. The study proposes to: 1. Evaluate the performance of the investigational STARgraft-2 compared to the ePTFE controls in the prior study and to published results, over a period of 6 months, with extended results to 1 year. 2. Verify safety of the STARgraft-2 multilayer construction in extended dialysis vascular access use. It is intended to enroll 25 subjects in this study.

NCT ID: NCT04768231 Not yet recruiting - Tuberculosis Clinical Trials

Rifampicin at High Dose for Difficult-to-Treat Tuberculosis

RIAlta
Start date: April 1, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety of rifampicin given at a dose three times as the standard one, in persons with tuberculosis that belong to groups that have not been widely included in previous trials.

NCT ID: NCT04747158 Completed - Clinical trials for SARS-CoV-2 Infection

COVID-19 Convalescent Plasma Therapy

TPCC
Start date: August 10, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

This study is an open-label trial in which hospitalized patients with risk factors of severe coronavirus disease 2019 [COVID-19] will be receive treatment with convalescent plasma (≤ 15 days from symptoms start).

NCT ID: NCT04659746 Recruiting - Quality of Life Clinical Trials

MejoraCare-Paraguay: mHealth Solution for Chronic Patients During the COVID-19 Outbreak in Paraguay

MejoraCare_P
Start date: December 9, 2020
Phase: N/A
Study type: Interventional

MejoraCare-Paraguay main objective is to test a mHealth solution (MejoraCare app) to be used for the education and empowerment of chronic patients (COPD, cancer, diabetes, heart disease. hypertension, etc.), and for supporting healthcare professionals to monitor and better understand patients' evolution during the COVID-19 outbreak (MejoraCare dashboard). This mHealth solution is built upon the Adhera platform developed by Salumedia Labs, which has already been validated in other therapeutic areas such as smoking cessation. MejoraCare is expected to raise awareness, educate and empower chronic patients, promoting behavioral changes towards adhering to healthier lifestyles thus reducing the risk of COVID-19 infection while providing emotional regulation support aiming at improving their mental health, quality of life, and emotional well-being.

NCT ID: NCT04538287 Recruiting - Conduction Defect Clinical Trials

AtaCor Subcostal Temporary Extravascular Pacing III Study

STEP III
Start date: October 3, 2020
Phase: N/A
Study type: Interventional

Third in-human study for the AtaCor Extravascular (EV) Temporary Pacing System to collect initial safety and performance data for the latest AtaCor System.

NCT ID: NCT04485520 Completed - Dental Plaque Clinical Trials

Efficacy of the Extract of Carica Papaya as an Inhibitor of Streptococcus Mutans

Start date: September 21, 2017
Phase: N/A
Study type: Interventional

Papaya has effects on oral pathogenic microorganisms, it also has anticoagulant quality, amebicidal action, antimicrobial, bacteriostatic and antifungal activity on different bacteria, especially on Streptococcus mutans, this can be exploited in the dental area. The objective of the study was to determine the efficacy of Carica Papaya peel extract (suckling) as an inhibitor of Streptococcus Mutans in students of the dental faculty of the National University of Caaguazú in 2018.

NCT ID: NCT04374929 Recruiting - Conduction Defect Clinical Trials

Subcostal Temporary Extracardiac Pacing II Study

STEP II
Start date: July 28, 2020
Phase: N/A
Study type: Interventional

Up to 12 subjects will be enrolled (up to 8 undergoing an AtaCor Temporary Pacing System procedure) in order to evaluate initial safety and performance of the AtaCor Temporary Pacing System when used with three (3) strategies for stabilizing AtaCor Temporary Pacing System electrical measurements over a two (2) to seven (7) day period. The three treatments are (1) Negative Pressure Wound Therapy, (2) Anti-Inflammatory Glucocorticoid and (3) increased electrode spacing. A control arm with no additional treatment is also included. Safety will be evaluated through analysis of all Adverse Events. Performance will be evaluated through (1) the incidence of successful StealthTrac Lead placement using the MACH I Delivery Tool, (2) electrical performance measurements, such as pacing capture thresholds, sensed R-wave amplitudes, pacing impedance and skeletal muscle stimulation at rest. Appropriate sensing and pacing capture will be ascertained from ECG Holter Monitor recordings during periods of in-hospital ambulation.

NCT ID: NCT04232774 Recruiting - Clinical trials for Type 2 Diabetes Mellitus With Circulatory Complciation

Neurotronic Ablation of Arteries for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities

NECTAR
Start date: November 4, 2019
Phase: N/A
Study type: Interventional

The study is to assess the safety and feasibility of chemical denervation of multiple artery beds for the treatment of Type 2 diabetes (T2DM) and its comorbidities.